Get the Stockscreener App
13.07
3.19%
-0.43
Alpha Tau Medical Ltd stock is traded at $13.07, with a volume of 398.84K.
It is down -3.19% in the last 24 hours and down -12.10% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$13.50
Open:
$13.14
24h Volume:
398.84K
Relative Volume:
0.98
Market Cap:
$1.21B
Revenue:
Net Income/Loss:
$-56.88M
P/E Ratio:
-19.79
EPS:
-0.6604
Net Cash Flow:
$-39.43M
1W Performance:
-6.64%
1M Performance:
-12.10%
6M Performance:
+65.86%
1Y Performance:
+237.73%
1-Day Range:
$13.02
$13.47
1-Week Range:
$13.34
$14.50
52-Week Range:
$3.43
$15.79
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
13.07 | 1.21B | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
510.25 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.45 | 82.51B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.45 | 53.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-26 | Initiated | Barclays | Overweight |
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Is Trial Enrollment Completion Altering The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Is Trial Enrollment Completion Altering The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Alpha Tau Medical (NasdaqCM:DRTS) Stock Forecast & Analyst Predictions - Simply Wall Street
Alpha Tau Medical stock hits 52-week high at 15.11 USD By Investing.com - Investing.com Australia
Is IMPACT Pilot Enrollment Completion Reshaping The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com Canada
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com Nigeria
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com India
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com UK
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough - Seeking Alpha
Alpha Tau Medical stock hits 52-week high at 15.11 USD By Investing.com - Investing.com South Africa
Alpha Tau to Participate in September Investor Conferences - Alpha Tau Medical
Alpha Tau to Participate in September Investor Conferences - The Manila Times
Alpha Tau to Participate in September Investor Conferences - Yahoo Finance
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment - Investing.com Nigeria
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment - Investing.com
Alpha Tau Medical (DRTS) finishes pancreatic IMPACT study signup - Stock Titan
Alpha Tau’s pancreatic cancer study grows from 12 to 48 patients as enrollment closes - Stock Titan
Alpha Tau Medical Ltd. Warrant (DRTSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Alpha Tau Medical Ltd. Warrant (DRTSW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Alpha Tau Medical Warrant (DRTSW) Rises 4.1% to $4.05 as Support HoldsStock Picks - careplusvn.com
Enlight (ENLT) Quarterly Results: The Company Releases Its Current Earnings Data in Latest Trading; Post-Report: Shares Move 0.41% Higher on the DayEarnings Stability Report - careplusvn.com
Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan - Stock Titan
Alpha Tau Medical (NASDAQ:DRTS) Sets New 1-Year HighHere's What Happened - MarketBeat
Alpha Tau Medical stock hits 52-week high at 14.79 USD - Investing.com
Alpha Tau Medical stock hits 52-week high at 14.79 USD - Investing.com Canada
Alpha Tau’s Clinical Momentum Put Its Cancer Tech On The Map - Finimize
Price to sales forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Alpha (DRTS) Quarter in Focus: EPS Does Not Reach the Reported Estimate; Share Response - careplusvn.com
Alpha (DRTS) Quarter in Focus: EPS Does Not Reach the Reported Estimate; Share Response - dars.gov.et
Alpha (DRTS) Quarter in Focus: EPS Does Not Reach the Reported Estimate; Share Response: Shares Finish 0.35% Lower for the Current SessionEarnings Miss Alert - dars.gov.et
Alpha (DRTS) Quarter in Focus: EPS Does Not Reach the Reported Estimate; Share Response - dars.gov.et
Price to earnings forward of Alpha Tau Medical Ltd. – BOATS:DRTSW - TradingView
Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy? - simplywall.st
Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy? - simplywall.st
Alpha Tau Medical Ltd.: Fundamental Analysis and Financial Ratings | DRTS | IL0011839383 - marketscreener.com
Alpha Tau Medical (XTAE:DRTS) Cyclically Adjusted Price-to-FCF : (As of Aug. 15, 2026) - GuruFocus
Alpha Tau Medical (XTAE:DRTS) Shiller PE Ratio : (As of Aug. 21, 2026) - GuruFocus
DRTS Forecast — Price Target — Prediction for 2027 - TradingView
Q3 EPS Estimate for Alpha Tau Medical Decreased by Analyst - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 5.4% Following Insider Selling - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock - MarketBeat
H.C. Wainwright raises Alpha Tau Medical stock price target to $16 - Investing.com
H.C. Wainwright raises Alpha Tau Medical stock price target to $16 - Investing.com Nigeria
Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer - Alpha Tau Medical
H.C. Wainwright raises Alpha Tau Medical stock price target to $16 - Investing.com South Africa
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Tau Medical Ltd Stock (DRTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levy Raphi | Chief Financial Officer |
Aug 21 '26 |
Sale |
15.00 |
2,871 |
43,073 |
90,180 |
| Raphael (Raphi) Aryeh Levy | Officer |
Aug 21 '26 |
Proposed Sale |
14.36 |
5,000 |
71,800 |
0 |
| Levy Raphi | Chief Financial Officer |
Aug 11 '26 |
Option Exercise |
2.98 |
17,730 |
52,835 |
107,910 |
| Levy Raphi | Chief Financial Officer |
Aug 11 '26 |
Sale |
14.00 |
17,730 |
248,277 |
90,180 |
| Levy Raphi | Chief Financial Officer |
Jul 06 '26 |
Option Exercise |
2.98 |
2,270 |
6,765 |
92,450 |
| Levy Raphi | Chief Financial Officer |
Jul 06 '26 |
Sale |
14.00 |
2,270 |
31,782 |
90,180 |
| Levy Raphi | Officer |
Jul 06 '26 |
Proposed Sale |
13.23 |
20,000 |
264,600 |
0 |
| Levy Raphi | Chief Financial Officer |
Jul 02 '26 |
Option Exercise |
2.98 |
17,873 |
53,262 |
108,053 |
| Levy Raphi | Chief Financial Officer |
Jul 02 '26 |
Sale |
13.00 |
17,873 |
232,397 |
90,180 |
| Levy Raphi | Chief Financial Officer |
Jul 01 '26 |
Option Exercise |
2.98 |
2,127 |
6,338 |
92,307 |
6.41%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):